Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1B | Q92523 | 1/20 | 0.61 |
| ▸ | CES2 | O00748 | 4/20 | 0.48 |
| ▸ | CES1 | P23141 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 3/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | MASP2 | O00187 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888848 | 0.86 | CES2 (0.55) | CES2CES1MAPTKDM4EHIF1A | |
| SCHEMBL7611819 | 0.86 | CPT1B (0.78) | CPT1BCES2CES1PTPRCPTPN1 | |
| Hydrochloric Acid SCHEMBL28122115 | 0.83 | CES2 (0.52) | CES2CES1MAPTKDM4EHIF1A | |
| Hydrochloric Acid SCHEMBL29249310 | 0.83 | CPT1B (0.74) | CPT1BCES2CES1PTPRCPTPN1 | |
| SCHEMBL7887870 | 0.82 | CES2 (0.75) | CES2CES1MAPTKDM4ELMNA | |
| SCHEMBL10405285 | 0.81 | CPT1B (0.41) | CPT1BCES2CES1MAPTKDM4E | |
| Oxalic Acid SCHEMBL6915099 | 0.80 | MAPT (0.57) | MAPTKDM4EHIF1ASLC22A6SLC22A8 | |
| SCHEMBL7030327 | 0.79 | MASP2 (0.50) | CES2CES1MAPTKDM4EHIF1A | |
| SCHEMBL27523102 | 0.79 | CPT1B (0.61) | CPT1BCES2CES1MAPTKMT2A | |
| Aminobenzoic Acid SCHEMBL8249 | 0.78 | TSHR (0.71) | CES2CES1MAPTKDM4EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024091437-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230359119-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| US-7442485-B2 | Lithographic process involving on press development | FUJIFILM CORPORATION (JP) | 2008-10-28 | — | — | US | disclosed |
| CN-101198607-A | Phenylacetamides suitable as protein kinase inhibitors | NOVARTIS AG (CH) | 2008-06-11 | — | — | CN | disclosed |
| EP-1484177-B1 | Lithographic process involving on press development | FUJIFILM CORP (JP) | 2007-08-29 | — | — | EP | disclosed |
| US-20050016402-A1 | Lithographic process involving on press development | FUJI PHOTO FILM CO., LTD. | 2005-01-27 | — | — | US | disclosed |
| EP-1484177-A2 | Lithographic process involving on press development | FUJI PHOTO FILM CO., LTD. (JP) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003055866-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | disclosed |
| EP-0747756-B1 | Photographic materials | AGFA GEVAERT NV (BE) | 2000-05-24 | — | — | EP | disclosed |
| US-5252707-A | Controlling metabolic procersses | MITSUI TOATSU CHEMICALS INCORPORATED (JP) | 1993-10-12 | — | — | US | disclosed |
| EP-0445299-A1 | INOSITOL DERIVATIVE AND PRODUCTION THEREOF | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | ADCY3, ADCY8, ADCY7 | CPT1B 3798/4885CES2 2935/4885CES1 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.